For that reason, we have collated published information on the benefit–risk profile of emicizumab, including long-term safety data, together with educational materials on post-marketing safety reporting and the pharmacovigilance process, which are available for all healthcare professionals to access on this website. We are also committed to ensuring that patient organisations for haemophilia and bleeding disorders continue to receive appropriate information regarding the safety and efficacy of emicizumab in a timely manner, so they may inform the patient communities that they serve.
Our promise and commitment to the haemophilia community remains unchanged and we will continue to listen, respond and partner with members of this community so that together we can make a collective effort for a continued dialogue to protect patient safety. We hope that you find the information on this website useful in informing your treatment decisions.
This website has been created to provide healthcare professionals with information regarding emicizumab from available clinical research data, real-world data and data from registries.
Information about the importance of safety reporting and roles and responsibilities related to itLearn more
Links to external guidance documents on the clinical use of emicizumabLearn more